<DOC>
	<DOCNO>NCT00077805</DOCNO>
	<brief_summary>Primary objective : - To demonstrate superiority enoxaparin 40 mg sc qd prevention VTE compare UFH ( unfractionated heparin ) 5000 U sc q12 hour give 10 ± 4 day follow acute ischemic stroke . Secondary objective : - To compare incidence VTE 2 treatment group 30 , 60 , 90 day time randomization - To compare neurologic outcome 2 treatment group , include incidence stroke recurrence , rate stroke progression , patient functional status , 10 ± 4 day treatment , 30 , 60 , 90 day time randomization - To evaluate safety use enoxaparin compare UFH VTE prevention patient follow acute ischemic stroke</brief_summary>
	<brief_title>PREVAIL : PREvention VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE : Venous Thromboembolism - LMWH : Low Molecular Weight Heparin )</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Inclusion criterion : Acute ischemic stroke , territory , appropriate neuroradiologic study ( head CT scan brain MRI scan ) provide result consistent non hemorrhagic stroke Onset symptom qualify stroke within 48 hour prior randomization . In patient receive thrombolytic therapy acute stroke , tissuetype plasminogen activator ( tPA ) , administration study drug may start least 24 hour completion thrombolytic therapy Significant motor impairment leg , indicate NIHSS score ≥2 item 6 Inability walk without assistance Exclusion criterion : Females pregnant , breastfeeding , childbearing potential use medically acceptable effective contraception Clinical evidence VTE screen Any evidence active bleeding basis clinical judgment Prior history intracranial hemorrhage ( include screen ) Spinal epidural analgesia lumbar puncture within precede 24 hour Thrombolytic therapy ( e.g. , tPA ) intraarterial thrombolytic therapy within precede 24 hours.Thrombolytic therapy permit treatment acute stroke must complete 24 hour prior randomization . Comatose screen ( NIHSS score ≥2 item 1a ) Known suspected cerebral aneurysm arteriovenous malformation Confirmed malignancy may pose increase risk bleed otherwise compromise followup outcome assessment ( e.g. , lung cancer ) Impaired hemostasis , i.e. , know suspect coagulopathy ( acquire inherit ) ; baseline platelet count &lt; 100,000/mm3 ; aPTT 1.5 X laboratory upper limit normal ; international normalize ratio ( INR ) &gt; 1.5 Major surgery recent major trauma within previous 3 month Anticipated need fulldose treatment therapeutic level anticoagulant ( LMWH , UFH , oral anticoagulant ) , e.g. , cardiogenic source embolism dissection Treatment LMWH UFH prophylactic dose 48 hour prior randomization ( patient receive LMWH UFH le 48 hour prior randomization may randomize ) Allergy heparin enoxaparin sodium , know hypersensitivity heparin , enoxaparin , pork product History heparin enoxaparin induce thrombocytopenia and/or thrombosis ( heparininduced thrombocytopenia [ HIT ] , heparinassociated thrombocytopenia [ HAT ] , heparininduced thrombotic thrombocytopenia syndrome [ HITTS ] ) History hypersensitivity iodinate contrast medium and/or iodine Bacterial endocarditis Prosthetic heart valve Known suspect severe anemia ( Hg &lt; 10.0 g/dL ) Uncontrolled arterial hypertension ( systolic blood pressure [ BP ] &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) time randomization clinical hypertensive urgency Any clinically relevant serious disease , include severe liver disease renal failure [ creatinine clearance &lt; 30 mL/min least two occasion ] . Treatment investigational agent device within previous 30 day , plan use investigational drug device , previous enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>